Jim Cramer's Mad Money Stock Recap April 9
By Any Other Name: Rosetta Resources (NasdaqGS: ROSE)
Cramer told investors to take a look at ROSE, a small, often-overlooked gas company which he says is "criminally mispriced" since it purchased Calpine Powers oil and natural gas assets for much less than they were worth. He comments ROSE is a "$35 stock, masquerading as a $21 name" and the assets it purchased were worth two and a half times the $1.5 billion ROSE paid in 2005. The one concern keeping ROSE back is Calpine's creditors may want to reclaim Calpine's assets from ROSE, but Cramer feels any attempt will fail, because " ... 'it is very hard to get this 'fraudulent conveyance' stuff." Although Cramer would wait a couple of days and use limit orders, he would definitely back up the truck and buy ROSE.
The Next Big Thing in Biotech: Incyte (NasdaqGM: INCY)
Cramer recalls how he "nailed" Nastech Pharmaceuticals in March, calls Incyte the next Nastech and "the stuff dreams are made of." With $330 million in cash, Incyte is a company that trades on hope, comments Cramer, and such companies are good investments if they are developing drugs for a variety of markets and have big end markets. Currently, INCY is producing drugs for HIV, inflammation and cancer, areas with "tremendous" potential. Although INCY has yet to see a Phase III drug, "it has potentially positive catalysts coming out soon," and Cramer would buy INCY before it releases Phase I and Phase II data later in the year. He would wait until Thursday and pick up INCY at $7.
Consolation Prizes: Valueclick (NasdaqGS: VCLK) and aQuantive (NasdaqGS: AQNT)
The real winner in the bidding war between Google and Microsoft over Doubleclick will be VCLK or AQNT, said Cramer, since the "loser" will buy either one of these companies. In addition, Time Warner and Yahoo have also been looking at VCLK and AQNT. Even if no one buys the companies, Cramer is bullish on them for their earnings alone; "The stocks can hold their own if they don't get acquired."
CEO Interview: Jordan Greenhall of DivX (NasdaqGM: DIVX)
Jordan Greenhall commented DIVX's great quarter wasn't a surprise with "strong performance" across the board. When asked to explain what his company does, Greenhall said the object is "to take Internet at the center and move it out to any device you can think of." When Cramer asked about a secondary offering, Greenhall replied DIVX is not considering that strategy right now. After the interview, Cramer said, "This stock is going higher than it did after-hours... Up 10% is not enough. This stock is rocking again."
Published by SeekingAlphaLabels: AQNT, DIVX, Hot Stocks, INCY, Jim Cramer, Mad Money, ROSE, VCLK
posted by Stock Administrator @ 10:20 AM
0 Comments
Jim Cramer's Mad Money Stock Recap April 9
By Any Other Name: Rosetta Resources (NasdaqGS: ROSE)
Cramer told investors to take a look at ROSE, a small, often-overlooked gas company which he says is "criminally mispriced" since it purchased Calpine Powers oil and natural gas assets for much less than they were worth. He comments ROSE is a "$35 stock, masquerading as a $21 name" and the assets it purchased were worth two and a half times the $1.5 billion ROSE paid in 2005. The one concern keeping ROSE back is Calpine's creditors may want to reclaim Calpine's assets from ROSE, but Cramer feels any attempt will fail, because " ... 'it is very hard to get this 'fraudulent conveyance' stuff." Although Cramer would wait a couple of days and use limit orders, he would definitely back up the truck and buy ROSE.
The Next Big Thing in Biotech: Incyte (NasdaqGM: INCY)
Cramer recalls how he "nailed" Nastech Pharmaceuticals in March, calls Incyte the next Nastech and "the stuff dreams are made of." With $330 million in cash, Incyte is a company that trades on hope, comments Cramer, and such companies are good investments if they are developing drugs for a variety of markets and have big end markets. Currently, INCY is producing drugs for HIV, inflammation and cancer, areas with "tremendous" potential. Although INCY has yet to see a Phase III drug, "it has potentially positive catalysts coming out soon," and Cramer would buy INCY before it releases Phase I and Phase II data later in the year. He would wait until Thursday and pick up INCY at $7.
Consolation Prizes: Valueclick (NasdaqGS: VCLK) and aQuantive (NasdaqGS: AQNT)
The real winner in the bidding war between Google and Microsoft over Doubleclick will be VCLK or AQNT, said Cramer, since the "loser" will buy either one of these companies. In addition, Time Warner and Yahoo have also been looking at VCLK and AQNT. Even if no one buys the companies, Cramer is bullish on them for their earnings alone; "The stocks can hold their own if they don't get acquired."
CEO Interview: Jordan Greenhall of DivX (NasdaqGM: DIVX)
Jordan Greenhall commented DIVX's great quarter wasn't a surprise with "strong performance" across the board. When asked to explain what his company does, Greenhall said the object is "to take Internet at the center and move it out to any device you can think of." When Cramer asked about a secondary offering, Greenhall replied DIVX is not considering that strategy right now. After the interview, Cramer said, "This stock is going higher than it did after-hours... Up 10% is not enough. This stock is rocking again."
Published by SeekingAlpha
Cramer told investors to take a look at ROSE, a small, often-overlooked gas company which he says is "criminally mispriced" since it purchased Calpine Powers oil and natural gas assets for much less than they were worth. He comments ROSE is a "$35 stock, masquerading as a $21 name" and the assets it purchased were worth two and a half times the $1.5 billion ROSE paid in 2005. The one concern keeping ROSE back is Calpine's creditors may want to reclaim Calpine's assets from ROSE, but Cramer feels any attempt will fail, because " ... 'it is very hard to get this 'fraudulent conveyance' stuff." Although Cramer would wait a couple of days and use limit orders, he would definitely back up the truck and buy ROSE.
The Next Big Thing in Biotech: Incyte (NasdaqGM: INCY)
Cramer recalls how he "nailed" Nastech Pharmaceuticals in March, calls Incyte the next Nastech and "the stuff dreams are made of." With $330 million in cash, Incyte is a company that trades on hope, comments Cramer, and such companies are good investments if they are developing drugs for a variety of markets and have big end markets. Currently, INCY is producing drugs for HIV, inflammation and cancer, areas with "tremendous" potential. Although INCY has yet to see a Phase III drug, "it has potentially positive catalysts coming out soon," and Cramer would buy INCY before it releases Phase I and Phase II data later in the year. He would wait until Thursday and pick up INCY at $7.
Consolation Prizes: Valueclick (NasdaqGS: VCLK) and aQuantive (NasdaqGS: AQNT)
The real winner in the bidding war between Google and Microsoft over Doubleclick will be VCLK or AQNT, said Cramer, since the "loser" will buy either one of these companies. In addition, Time Warner and Yahoo have also been looking at VCLK and AQNT. Even if no one buys the companies, Cramer is bullish on them for their earnings alone; "The stocks can hold their own if they don't get acquired."
CEO Interview: Jordan Greenhall of DivX (NasdaqGM: DIVX)
Jordan Greenhall commented DIVX's great quarter wasn't a surprise with "strong performance" across the board. When asked to explain what his company does, Greenhall said the object is "to take Internet at the center and move it out to any device you can think of." When Cramer asked about a secondary offering, Greenhall replied DIVX is not considering that strategy right now. After the interview, Cramer said, "This stock is going higher than it did after-hours... Up 10% is not enough. This stock is rocking again."
Published by SeekingAlpha
Labels: AQNT, DIVX, Hot Stocks, INCY, Jim Cramer, Mad Money, ROSE, VCLK
posted by Stock Administrator @ 10:20 AM
0 Comments
